CancerCare is a national nonprofit organization that provides free emotional, practical and financial support to anyone affected by cancer. 800-813-HOPE
New York, New York
Joined April 2009
- Tweets7.8K
- Following1.6K
- Followers20.7K
- Likes2.5K
Pinned Tweet
Last year, @CancerCare provided 150,508 services to people diagnosed with cancer, caregivers and bereaved individuals. Our emotional, practical and financial support programs continued to offer help and hope to anyone affected by cancer.
Learn more at cancercare.org.
CancerCare retweeted
Today, we have approved a new treatment regimen for adults with muscle-invasive bladder cancer who are unable to receive or have declined cisplatin-based chemotherapy. fda.gov/drugs/cancer-approva…
What are biomarkers and what can biomarker testing mean for your cancer and your care? Learn more by visiting cancercare.org/biomarkers
#CancerBiomarkers #CancerBiomarkerDay
1
64
FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor
fda.gov/drugs/cancer-approva…
118
CancerCare retweeted
Today, FDA approved a treatment for symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity.
fda.gov/drugs/cancer-approva…
ALT Blue and yellow graphic titled "Drug Approval" by the FDA. Text reads: "FDA approves a treatment for symptomatic tenosynovial giant cell tumor." Icons of medication bottles and a syringe are displayed.
CancerCare retweeted
Join us this Sunday, 11/15, at CancerCare’s Annual Walk for Hope!
For more than 80 years, @CancerCare has provided free emotional and practical support for people with cancer, caregivers, loved ones and the bereaved.
CancerCare retweeted
Today, FDA approved a treatment for adult patients with recurrent or metastatic head and neck squamous cell cancer whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.
This is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies. fda.gov/news-events/press-an…
CancerCare retweeted
Explore non-squamous non-small cell lung cancer #ClinicalStudy options through myTRIAList. Our study finder features plain-language study overview videos, including the TeliMET #NSCLC-04 study, that help make study information more accessible. Learn more: bit.ly/4A7BNfO
We brought the Long Island cancer community together for a free, fall-inspired afternoon of pumpkin painting, creativity, and connection.
Explore more of our community programs: loom.ly/eViNF0w
1
98
Would you consider using AI to help find a cancer clinical trial? This month, CancerCare wants to hear your thoughts and experiences with AI tools to find #clinicaltrials.
Share your perspective through our Question of the Month poll: cancercare.org/question
74
CancerCare retweeted
A @PioneerPolicy and @CancerCare study found that 340B hospitals spend an average of just 2.16% of operating expenses on charity care. Non-340B hospitals spend 2.82%.
Why are hospitals receiving billions in discounts to help vulnerable patients providing less charity care?
forbes.com/sites/sallypipes/…
CancerCare retweeted
Understanding #ClinicalTrials can feel overwhelming. Noelle Cloven, MD, from Texas Oncology, shares insights in the RAINFOL-03 study video on myTRIAList. Explore possible clinical trial options and learn more here: bit.ly/4ssM3wu
#EndometrialCancer #CancerResearch
FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations
fda.gov/drugs/resources-info…
1
128
CancerCare retweeted
NEWS: Today, FDA approved a new treatment for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. fda.gov/drugs/resources-info…
CancerCare retweeted
New in @Forbes: Sally Pipes cites research from Pioneer and @CancerCare finding 340B hospitals spent an average of 2.16% of operating expenses on charity care vs. 2.82% for non-340B hospitals. Read it here: bit.ly/4sdBqgK 🔒
CancerCare retweeted
#340B reform must be a priority to improve access to healthcare for cancer patients, according to Kim Czubaruk of @CancerCare in a new opinion. Congress should take action to improve 340B transparency and accountability so patients benefit. Read more in @RealClearHealth: realclearhealth.com/articles…
CancerCare retweeted
FDA has granted accelerated approval of an immunotherapy for adults with previously untreated stage II or III locally advanced rectal cancer whose tumors are dMMR or MSI-H.
In a phase 2 study, almost three-fourths of patients did not need surgery, radiotherapy, or chemotherapy after a median follow-up of more than 2 years. For eligible patients, treatment may help avoid chemotherapy, radiation and surgery and their lasting effects.
This is the 11th approval under the Commissioner’s National Priority Voucher pilot program.
ALT Illustration showing two cells representing immunotherapy interacting, with a small inset image of a highlighted colon. Text states: "FDA grants accelerated approval of immunotherapy for certain patients with rectal cancer.
CancerCare retweeted
📋 New post-transplant GvHD symptom tracker
Record your symptoms and track changes over time with our downloadable tracker.
💻 Complete digitally
🖨️ Or print and fill it in by hand
👩⚕️ Share with your healthcare team to help identify patterns or changes.
🔗 Download the tracker here: bit.ly/4jfm4pG
#GvHD
Independently supported by Therakos. Funders are allowed no influence.
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer
fda.gov/drugs/resources-info…
142
CancerCare retweeted
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval.
fda.gov/drugs/resources-info…
ALT The image announces that the FDA has approved the first treatment for patients with BCG-unresponsive bladder cancer. It features a purple and orange awareness ribbon and the FDA logo.
CancerCare retweeted
Proud to have our CEO @AnjeeDavis at the 2026 @MilkenInstitute Patient Advocacy Forum in Washington, DC, where she spoke on "Patient Advocacy in the Age of AI, Data, and Digital Trust" about keeping AI-enabled health information accurate, trusted, and grounded in lived experience.
It was great to connect with fellow cancer advocates @JulieFleshman, CEO of @PanCAN, and Christine Verini, RPh, CEO of @CancerCare, who share our commitment to putting patients first. Thank you to the Milken Institute for bringing us together! 💙
Access to trustworthy information matters. Find colorectal cancer resources for patients and families at fightcrc.org/resources.
